Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety/Efficacy of rFIX-R vs BeneFIX in Hemophilia B
NCT00093210Phase 3Completed
- Sponsor
- Pfizer
- Modality
- Recombinant Proteins and Enzymes
01
Overview
Phase 3, randomised, double-blind trial of coagulation factor ix recombinant in hemophilia B (HB) (2 arms), sponsored by Pfizer. Primary endpoints: Maximum Plasma Concentration at 72 hours and Area Under the Curve at 72 hours. Status: completed.
02
Drugs
coagulation factor ix recombinant
03
Conditions
hemophilia B (HB)
Beyond the preview
Go deeper on NCT00093210.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00093210.